TME Pharma N.V. (ALTME.PA)

EUR 0.06

(1.1%)

Total Liabilities Summary of TME Pharma N.V.

  • TME Pharma N.V.'s latest annual total liabilities in 2023 was 2.78 Million EUR , down -57.24% from previous year.
  • TME Pharma N.V.'s latest quarterly total liabilities in 2024 Q2 was 1.37 Million EUR , down 0.0% from previous quarter.
  • TME Pharma N.V. reported annual total liabilities of 6.51 Million EUR in 2022, up 23.68% from previous year.
  • TME Pharma N.V. reported annual total liabilities of 5.26 Million EUR in 2021, up 78.15% from previous year.
  • TME Pharma N.V. reported quarterly total liabilities of 2.78 Million EUR for 2023 FY, down -57.24% from previous quarter.
  • TME Pharma N.V. reported quarterly total liabilities of 2.78 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Total Liabilities Chart of TME Pharma N.V. (2023 - 2014)

Historical Annual Total Liabilities of TME Pharma N.V. (2023 - 2014)

Year Total Liabilities Total Liabilities Growth
2023 2.78 Million EUR -57.24%
2022 6.51 Million EUR 23.68%
2021 5.26 Million EUR 78.15%
2020 2.95 Million EUR -17.57%
2019 3.58 Million EUR -49.67%
2018 7.12 Million EUR 46.97%
2017 4.84 Million EUR -9.4%
2016 5.35 Million EUR -59.07%
2015 13.07 Million EUR 40.07%
2014 9.33 Million EUR 0.0%

Peer Total Liabilities Comparison of TME Pharma N.V.

Name Total Liabilities Total Liabilities Difference
ABIONYX Pharma SA 6.91 Million EUR 59.708%
ABIVAX Société Anonyme 131.05 Million EUR 97.875%
Adocia SA 31.87 Million EUR 91.261%
Aelis Farma SA 13.08 Million EUR 78.708%
Biophytis S.A. 15.84 Million EUR 82.428%
Advicenne S.A. 24.37 Million EUR 88.575%
genOway Société anonyme 14.45 Million EUR 80.739%
IntegraGen SA 5.97 Million EUR 53.427%
Medesis Pharma S.A. 6.42 Million EUR 56.662%
Neovacs S.A. 3.71 Million EUR 24.976%
NFL Biosciences SA 3.62 Million EUR 23.081%
Plant Advanced Technologies SA 6.78 Million EUR 58.938%
Quantum Genomics Société Anonyme 3.31 Million EUR 15.864%
Sensorion SA 13.22 Million EUR 78.945%
Theranexus Société Anonyme 5.01 Million EUR 44.48%
Valbiotis SA 13.7 Million EUR 79.683%
TheraVet SA 1.48 Million EUR -87.543%
Valerio Therapeutics Société anonyme 20.46 Million EUR 86.393%
argenx SE 402.79 Million EUR 99.309%
BioSenic S.A. 32.26 Million EUR 91.368%
Celyad Oncology SA 9.97 Million EUR 72.089%
DBV Technologies S.A. 38.74 Million USD 92.812%
Galapagos NV 1.56 Billion EUR 99.822%
Genfit S.A. 105.92 Million EUR 97.371%
GeNeuro SA 20.13 Million EUR 86.172%
Hyloris Pharmaceuticals SA 8.61 Million EUR 67.661%
Innate Pharma S.A. 132.29 Million EUR 97.895%
Inventiva S.A. 101.59 Million EUR 97.259%
MaaT Pharma SA 22.46 Million EUR 87.603%
MedinCell S.A. 77.77 Million EUR 96.419%
Nanobiotix S.A. 95.74 Million EUR 97.091%
Onward Medical N.V. 25.69 Million EUR 89.163%
Oryzon Genomics S.A. 25.12 Million EUR 88.916%
OSE Immunotherapeutics SA 59.07 Million EUR 95.286%
Oxurion NV 19.73 Million EUR 85.889%
Pharming Group N.V. 228.28 Million EUR 98.78%
Poxel S.A. 53.9 Million EUR 94.833%
GenSight Biologics S.A. 34.72 Million EUR 91.98%
Transgene SA 26.51 Million EUR 89.497%
Financière de Tubize SA 123.65 Million EUR 97.748%
UCB SA 6.56 Billion EUR 99.958%
Valneva SE 341.14 Million EUR 99.184%
Vivoryon Therapeutics N.V. 4.54 Million EUR 38.751%